Skip to Content

Hydergine (ergoloid mesylates) Disease Interactions

There are 2 disease interactions with Hydergine (ergoloid mesylates):

Major

Amine ergots (applies to Hydergine) cardiovascular adverse effects

Major Potential Hazard, Moderate plausibility. Applicable conditions: Tachyarrhythmia

The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects. Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors. Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes. Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations. Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease. Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis. Close monitoring of cardiovascular status is highly recommended during therapy.

References

  1. "Product Information. Ergotrate Maleate (ergonovine)." Bedford, Bedford, OH.
  2. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Major

Ergoloid mesylates (applies to Hydergine) psychosis

Major Potential Hazard, Moderate plausibility.

The use of ergoloid mesylates is contraindicated in patients with acute or chronic psychosis, regardless of etiology.

References

  1. "Product Information. Gerimal (ergoloid mesylates)." Novartis Pharmaceuticals, East Hanover, NJ.

Hydergine (ergoloid mesylates) drug interactions

There is 1 drug interaction with Hydergine (ergoloid mesylates)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.